Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERFUMER-70: Treatment Holiday Strategy in Metastatic Clear Cell Renal Cell Carcinoma
NCT07615348Phase 2Recruiting
- Sponsor
- Jinling Hospital
- Start
- Jun 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in clear cell renal cell carcinoma (ccRCC), sponsored by Jinling Hospital. Primary endpoint: Treatment-free survival rate at 12 months. Started Jun 2026; status: recruiting.
02
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07615348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07615348.